Skip to lesson
OncoGuideeducationDiana’s wiki
THE EDUCATION LIBRARY

B2M (beta-2 microglobulin)

In one sentence

Beta-2 microglobulin supports the assembly and stable surface expression of classical human leukocyte antigen class-I complexes.

The intuition

A shared support piece can affect many display cases. B2M is not the antigen being selected for a vaccine; it helps the class-I system display antigens. The analogy breaks if we treat every presentation pathway as the same structure.

How it works

Classical human leukocyte antigen (HLA) class I contains a heavy chain, a peptide and beta-2 microglobulin (B2M). Functional B2M supports normal assembly and surface expression. Many conventional CD8 T-cell responses depend on this display system.

Loss of functional B2M can impair many class-I targets at once. That differs from losing a single HLA allele, which may leave other presenting alleles usable. Class-II presentation does not use B2M by the same mechanism.

A reported DNA variant, low RNA level and absent surface class-I protein are different observations. Variant interpretation, copy number, protein assessment and functional experiments help establish whether presentation is actually impaired. A blood concentration of B2M is also a different measurement from tumor-cell presentation.

Why it matters in cancer

Vaccines and engineered T-cell receptors can share a class-I dependency. A surface-antigen receptor may avoid that recognition requirement, but still needs a suitable target, access, function and acceptable safety.

Worked example

A fictional design uses several peptides presented by different class-I alleles. If all depend on a shared B2M defect, the number of peptides does not create independent escape protection. If only one allele is lost instead, retained alleles may still present other targets.

Common confusions

  • B2M loss is not identical to losing one HLA allele.
  • A B2M variant is not automatically complete functional loss.
  • Reduced class-I display does not guarantee natural killer-cell killing.

Sources and scope

Source check: October 8, 2026. This is a mechanism explanation, not a treatment recommendation. Expert and learner review remain pending.

Used in